APYX Apyx Medical

Apyx Medical Corporation to Participate in the Canaccord Genuity 45th Annual Growth Conference

Apyx Medical Corporation to Participate in the Canaccord Genuity 45th Annual Growth Conference

CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System, today announced that management will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, in Boston, MA.

Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 12, 2025, at 4:00pm ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via , and a replay will be available on the Events section of Apyx Medical’s Investor Relations website at .

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and now the AYON Body Contouring System in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at 

Investor Relations Contact:

Jeremy Feffer

Managing Director

LifeSci Advisors

OP: 212-915-2568 

  



EN
30/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apyx Medical

 PRESS RELEASE

Apyx Medical Corporation to Participate in the Canaccord Genuity 45th ...

Apyx Medical Corporation to Participate in the Canaccord Genuity 45th Annual Growth Conference CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that management will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, in Boston, MA. Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt H...

 PRESS RELEASE

Apyx Medical Corporation Announces Launch of Renuvion® in China

Apyx Medical Corporation Announces Launch of Renuvion® in China Strong clinical interest and early procedures completed Entered into distribution agreement with GlamMoon, a division of BeauCare Clinics Investment Co., Ltd. post-initial market clearance CLEARWATER, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced the launch of Renuvion® in China as part of its international commercialization strategy. A targeted sales and marketing campaign for Renuvion is being conducted through a distribution agreement cover...

 PRESS RELEASE

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025...

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the second quarter of fiscal year 2025 will be released after markets closes on Thursday, August 7th. Management will host a conference call at 4:30 p.m. Eastern Time on Th...

 PRESS RELEASE

Apyx Medical Corporation Receives FDA Clearance for the AYON Body Cont...

Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™ The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvio...

 PRESS RELEASE

Apyx Medical Corporation Reports First Quarter 2025 Financial Results

Apyx Medical Corporation Reports First Quarter 2025 Financial Results Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch